Simon, Christopher
Known title: President & CEOCIK: 0001674993
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Transaction History
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 9,681 | $545K | 5/15/2026 | View on chart |
| HAE | ▲ Buy | Grant | 78,344 | — | 5/15/2026 | View on chart |
| HAE | ▲ Buy | Grant | 66,666 | $0 | 5/30/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 26,234 | $1.8M | 5/30/2025 | View on chart |
| SHC | ▲ Buy | Grant | 19,132 | $0 | 5/22/2025 | View on chart |
| HAE | ▲ Buy | Grant | 21,405 | — | 5/16/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 7,089 | $498K | 5/16/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 2,391 | $166K | 5/15/2025 | View on chart |
| HAE | ▼ Sell | Other | 39,704 | $3.0M | 8/29/2024 | View on chart |
| HAE | ▲ Buy | Option Exercise | 104,516 | $4.4M | 6/6/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 71,335 | $6.2M | 6/6/2024 | View on chart |
| HAE | ▲ Buy | Grant | 106,062 | $0 | 5/28/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 41,736 | $4.0M | 5/28/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 4,037 | $386K | 5/17/2024 | View on chart |
| HAE | ▲ Buy | Grant | 14,624 | — | 5/17/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 1,907 | $181K | 5/16/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 1,480 | $143K | 5/15/2024 | View on chart |
| HAE | ▼ Sell | Gift | 38,900 | $0 | 3/11/2024 | View on chart |
| HAE | ▲ Buy | Option Exercise | 196,746 | $5.6M | 6/29/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 117,667 | $10.0M | 6/29/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 3,839 | $320K | 5/18/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 1,586 | $141K | 5/16/2023 | View on chart |
| HAE | ▲ Buy | Grant | 18,225 | — | 5/15/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 854 | $75K | 5/12/2023 | View on chart |
| HAE | ▼ Sell | Gift | 8,600 | $0 | 11/11/2022 | View on chart |
| HAE | ▼ Sell | Open Market | 1,148 | $72K | 6/13/2022 | View on chart |
| HAE | ▼ Sell | Open Market | 2,496 | $148K | 5/19/2022 | View on chart |
| HAE | ▼ Sell | Open Market | 832 | $47K | 5/16/2022 | View on chart |
| HAE | ▲ Buy | Grant | 26,041 | — | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.